Different population-level vaccination effectiveness for HPV types 16, 18, 6 and 11

Sexually Transmitted Infections

Volumn 87, Issue 1, 2011, Pages 41-43

  Brisson, Marc ^a,b   Van De Velde, Nicolas ^a,b   Boily, Marie Claude ^a,c  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; DRUG EFFICACY; GROUPS BY AGE; HEALTH PROGRAM; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; PREVALENCE; PRIORITY JOURNAL; PROTECTION; SEXUAL BEHAVIOR; STOCHASTIC MODEL; VACCINATION; VIRUS TRANSMISSION;

EID: 78751647833     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.2010.044412     Document Type: Article

References (10)

1. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
2. Wheeler CM, Hunt WC, Joste NE, et al. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009;101:475-87.
3. Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. Oxford, UK: Oxford University Press, 1991.
4. Trottier H, Mahmud S, Prado JC, et al. Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J Infect Dis 2008;197:1436-47. (Pubitemid 351706468)
5. Bogaards JA, Xiridou M, Coupé VM, et al. Model-based estimation of viral transmissibility and infection-induced resistance from the age-dependent prevalence of infection for 14 high-risk types of human papillomavirus. Am J Epidemiol 2010;171:817-25.
6. Van de Velde N, Brisson M, Boily MC. Understanding differences in predictions of HPV vaccine effectiveness: a comparative model-based analysis. Vaccine 2010;28:5473-84.
7. Ades S, Koushik A, Duarte-Franco E, et al. Selected class I and class II HLA alleles and haplotypes and risk of high-grade cervical intraepithelial neoplasia. Int J Cancer 2008;122:2820-6.
8. Richardson H, Kelsall G, Tellier P, et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 2003;12:485-90.
9. The Canadian Community Health Survey (CCHS), Cycle 3.1. 2005. http://www.statcan.gc.ca/concepts/health-sante/cycle3-1/index-eng.htm (accessed 21 Sep 2010).
10. Fairley CK, Hocking JS, Gurrin LC, et al. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009;85:499-502.